The Food and Drug Administration on Sunday issued an emergency use authorization for hydroxychloroquine and chloroquine, decades-old malaria drugs championed by President Donald Trump for coronavirus treatment despite scant evidence.
The agency allowed for the drugs to be “donated to the Strategic National Stockpile to be distributed and prescribed by doctors to hospitalized teen and adult patients with COVID-19, as appropriate, when a clinical trial is not available or feasible,” HHS said in a statement, announcing that Sandoz donated 30 million doses of hydroxychloroquine to the stockpile and Bayer donated 1 million doses of chloroquine.
The move was supported by the White House, part of a larger Trump-backed effort to speed the use of anti-malaria drugs as a potential therapy for a virus that has no proven treatment or cure. FDA already has allowed New York state to test administering the medication to seriously ill patients, and some hospitals have added it to their treatment protocols.
“Let’s see how it works,” Trump said at a press briefing on Sunday, referencing New York state’s efforts. “It may. It may not.”
“Scientists in America and around the world have identified multiple potential therapeutics for COVID19, including chloroquine and hydroxychloroquine,” HHS Secretary Alex Azar tweeted on Sunday night, praising Trump and the Emergency Use Authorization (EUA).
Career scientists have been skeptical of the effort, noting the lack of data on the drugs’ efficacy for coronavirus care and worried that it would siphon medication away from patients who need it for other conditions, calling instead for the agency to pursue its usual clinical trials. FDA’s move is expected to facilitate more access to the drugs by allowing more donations, and a second EUA is under consideration that would allow more manufacturers to produce it, said three officials.
Hydroxychloroquine, which is already available commercially in the United States, is commonly used to treat malaria, lupus and rheumatoid arthritis. The drug also has been touted as a therapy for coronavirus by an unusual assortment of investors, TV correspondents and even some advisers to the White House — including some advocates who overstated their claims and credentials — and been championed by guests on Fox News.
However, a growing number of lupus and arthritis patients have complained that they’ve been unable to fIll their prescriptions amid ongoing shortages, and reports have emerged that some physicians are hoarding the drug for themselves. Federal officials also have privately complained that Trump’s focus on anti-malaria drugs has distracted from efforts to investigate more promising therapies, and several scientists immediately panned the announcement.
“I would like to see who at FDA’s [Medical Countermeasures Initiative] signed off on this EUA despite the total lack of scientific evidence that chloroquine/hydroxychloroquine are beneficial in the treatment of COVID-19,” tweeted Luciana Borio, who served as FDA’s acting chief scientist between 2015 and 2017. “EUA is supposed to be issued when the evidence indicates that benefits outweigh the risks.”
Trump has pushed to experiment with new therapies and not wait on the usual clinical protocols, given the unprecedented nature of the coronavirus pandemic. Asked by a POLITICO reporter whether his agencies should wait for more evidence on anti-malaria drugs, the president on Friday stressed the need for speed, alluding to disagreements with infectious-disease specialist Anthony Fauci — one of several officials who has privately counseled the president not to rush on unproven medicines.
“I think Tony would disagree with me … [but] we have a pandemic, we have people dying now,” Trump said, adding that he’d recently spoken with FDA and been frustrated by the agency’s pace.
“They indicated that we’ll start working on it right away. It could take a year,” the president said. “I said what do you mean a year? We have to have it tonight.”
POLITICO
Leave a Reply
You must be logged in to post a comment.